---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-039431"
form_type: "8-K"
ticker: "XAGE"
cik: "0001842939"
company_name: "Longevity Health Holdings, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:55:25.828405+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Carmell completes sale of Axolotl Biologix, expects $4M annual cash burn reduction

## Summary
- Sale closed March 26; consideration: 3.845M common shares, 4,243 preferred shares, cancellation of $8M notes payable.
- Annualized cash burn expected to drop $4M based on AxoBio's January 2024 financials.
- Total debt reduction of $15.6M ($7.6M subsidiary debt + $8M notes payable).
- Tangible equity increased $7M from eliminating AxoBio's negative tangible equity.
- EPS dilution reduced 29% via cancellation of 8.09M fully diluted shares; 19.25M shares outstanding post-closing.

## SEC filing metadata
- accession: 0000950170-24-039431
- form_type: 8-K
- ticker: XAGE
- cik: 0001842939
- company_name: Longevity Health Holdings, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842939/000095017024039431/0000950170-24-039431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842939/000095017024039431/ctcx-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-039431
- JSON: https://secwatch.observer/filing/0000950170-24-039431.json
- Plain text: https://secwatch.observer/filing/0000950170-24-039431.txt

## Key facts
- M&A Transactions
  Longevity Health Holdings, Inc. completed a disposition involving Burns Ventures, LLC, H. Rodney Burns, AXO XP, LLC, Protein Genomics, LLC (collectively, the Buyers) for 3,845,337 shares of common stock, 4,243 shares of Series A Convertible Voting Preferred Stock, and cancellation of $8 million principal amount of notes payable (closed 2024-03-26).
  - Action: disposition
  - Counterparty: Burns Ventures, LLC, H. Rodney Burns, AXO XP, LLC, Protein Genomics, LLC (collectively, the Buyers)
  - Consideration: 3,845,337 shares of common stock, 4,243 shares of Series A Convertible Voting Preferred Stock, and cancellation of $8 million principal amount of notes payable
  - Closing: 2024-03-26
  source text: LLC, a Delaware corporation (“PGEN” and together with BVLLC, Burns, and AXPLLC, collectively, the “Buyers” and each, a “Buyer”). The consideration for the Sale consisted of (i) 3,845,337 shares of the Company’s common stock, $0.0001 par value per share, and 4,243 shares of the Company’s Series A Convertible Voting Preferred Stock, $0.0001 par value per share,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842939/000095017024039431/0000950170-24-039431-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.